Estari

Estari describes a three-part platform combining direct private equity investment, programmatic fund selection, and an in-house intelligence capability. The direct arm covers buyout, growth, and venture-stage companies. The fund selection arm runs systematic screening of European and global PE managers. The intelligence function supports both with top-down performance analysis and bottom-up deal assessment.

The firm's own materials cite investments in mRNA biotech, renewable energy, textile circularity, shared low-carbon mobility across Europe, and sustainable agricultural innovation. No specific portfolio-company names are disclosed publicly.

Estari states its founder brings experience across direct investment, fund structuring, and institutional advisory within the European PE ecosystem. No individual name, title, or investment committee structure is publicly disclosed. Operational leadership remains opaque.

No. Estari does not publicly disclose assets under management, deployment totals, or performance track-record data. The firm's scale is not verifiable from its website or primary public sources.

Estari does not describe a public sourcing model. It references a proprietary intelligence capability that covers screening, due diligence, and portfolio management, but does not disclose specific origination channels, network structures, or co-investor relationships.

Estari describes itself as a European private equity platform with institutional advisory capabilities, which suggests it may manage or advise external capital. However, it does not publicly disclose its legal structure, whether it holds a regulatory license, or the provenance of its investment capital.

Estari derives its name from Shabestari, a 14th-century Persian Sufi poet whose work explores unity and the idea that meaning comes through contribution rather than accumulation. The firm frames this as the philosophical anchor for its investment conviction — directing capital toward a more positive economy.